Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Sternberg

Showing results (391-400 of 564) with videos related to

Pageof 57
Sort By:
Prostate Cancer and Prostatic Diseases|January 25, 2017
Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAILA H Bryce, J J Alumkal, A Armstrong, et al.
Anticancer Research|January 31, 2025
Mesonephric Adenocarcinoma in a Young Male PatientDaniela Guevara, Nara Shin, Alexandra Boiko, et al.
Anticancer Research|January 31, 2025
Unusual Presentation of Advanced Urothelial Cancer in a Young PatientDaniela Guevara, Nara Shin, Alexandra Boiko, et al.
Cold Spring Harbor Molecular Case Studies|April 28, 2022
Tumor-immune microenvironment revealed by Imaging Mass Cytometry in a metastatic sarcomatoid urothelial carcinoma with a prolonged response to pembrolizumabHussein Alnajar, Hiranmayi Ravichandran, André Figueiredo Rendeiro, et al.
BMC Cancer|July 25, 2024
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 studyIrfan Cicin, Elizabeth R Plimack, Howard Gurney, et al.
BMC Cancer|August 23, 2023
Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER)Ariel E Marciscano, Sydney Wolfe, Xi Kathy Zhou, et al.
BJU International|August 30, 2012
Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failureHielke J Meulenbeld, Jean P Bleuse, Elio M Vinci, et al.
European Urology|January 30, 2025
Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 TrialJohann S de Bono, Meng He, Zhen Shi, et al.
JAMA Oncology|March 10, 2018
Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical TrialDana E Rathkopf, Tomasz M Beer, Yohann Loriot, et al.
Eclinicalmedicine|May 30, 2023
Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancerCelestia S Higano, Daniel J George, Neal D Shore, et al.
Pageof 57

Showing results (391-400 of 564) with videos related to

Sort By:
Pageof 57
Prostate Cancer and Prostatic Diseases|January 25, 2017
Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAILA H Bryce, J J Alumkal, A Armstrong, et al.
Anticancer Research|January 31, 2025
Mesonephric Adenocarcinoma in a Young Male PatientDaniela Guevara, Nara Shin, Alexandra Boiko, et al.
Anticancer Research|January 31, 2025
Unusual Presentation of Advanced Urothelial Cancer in a Young PatientDaniela Guevara, Nara Shin, Alexandra Boiko, et al.
Cold Spring Harbor Molecular Case Studies|April 28, 2022
Tumor-immune microenvironment revealed by Imaging Mass Cytometry in a metastatic sarcomatoid urothelial carcinoma with a prolonged response to pembrolizumabHussein Alnajar, Hiranmayi Ravichandran, André Figueiredo Rendeiro, et al.
BMC Cancer|July 25, 2024
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 studyIrfan Cicin, Elizabeth R Plimack, Howard Gurney, et al.
BMC Cancer|August 23, 2023
Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER)Ariel E Marciscano, Sydney Wolfe, Xi Kathy Zhou, et al.
BJU International|August 30, 2012
Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failureHielke J Meulenbeld, Jean P Bleuse, Elio M Vinci, et al.
European Urology|January 30, 2025
Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 TrialJohann S de Bono, Meng He, Zhen Shi, et al.
JAMA Oncology|March 10, 2018
Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical TrialDana E Rathkopf, Tomasz M Beer, Yohann Loriot, et al.
Eclinicalmedicine|May 30, 2023
Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancerCelestia S Higano, Daniel J George, Neal D Shore, et al.
Pageof 57